Search research articles
Contact Us
Filters
Showing results (41-50 of 44) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 44 results.
Journal of Immunology (Baltimore, Md. : 1950)
|
April 26, 2015
CD14++CD16+ Monocytes Are Enriched by Glucocorticoid Treatment and Are Functionally Attenuated in Driving Effector T Cell Responses
Baoying Liu, Ashwin Dhanda, Sima Hirani, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 17, 2015
Glucocorticoid-resistant Th17 cells are selectively attenuated by cyclosporine A
Lauren P Schewitz-Bowers, Philippa J P Lait, David A Copland, et al.
Immunity
|
November 18, 2018
Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function
Sarah L Buchan, Lang Dou, Marcus Remer, et al.
Cancer Cell
|
April 16, 2015
Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo
Ali Roghanian, Ingrid Teige, Linda Mårtensson, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 44) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 44 results.
Journal of Immunology (Baltimore, Md. : 1950)
|
April 26, 2015
CD14++CD16+ Monocytes Are Enriched by Glucocorticoid Treatment and Are Functionally Attenuated in Driving Effector T Cell Responses
Baoying Liu, Ashwin Dhanda, Sima Hirani, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 17, 2015
Glucocorticoid-resistant Th17 cells are selectively attenuated by cyclosporine A
Lauren P Schewitz-Bowers, Philippa J P Lait, David A Copland, et al.
Immunity
|
November 18, 2018
Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function
Sarah L Buchan, Lang Dou, Marcus Remer, et al.
Cancer Cell
|
April 16, 2015
Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo
Ali Roghanian, Ingrid Teige, Linda Mårtensson, et al.
Page
of 5